Abstract
Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Current Pharmaceutical Design
Title:Pharmacogenomics of Oral Antithrombotic Drugs
Volume: 22 Issue: 13
Author(s): Flavia Storelli, Youssef Daali, Jules Desmeules, Jean-Luc Reny and Pierre Fontana
Affiliation:
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Abstract: Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Export Options
About this article
Cite this article as:
Storelli Flavia, Daali Youssef, Desmeules Jules, Reny Jean-Luc and Fontana Pierre, Pharmacogenomics of Oral Antithrombotic Drugs, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208122845
DOI https://dx.doi.org/10.2174/1381612822666151208122845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Intervention for Cardiac Repair: A Clinical Perspective
Current Stem Cell Research & Therapy Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Current Molecular Medicine Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Biobanking in Atherosclerotic Disease, Opportunities and Pitfalls
Current Cardiology Reviews Subject Index to Volume 3
Current Gene Therapy Hypercholesterolemia and Endothelium Dysfunction: Role of Dietary Supplementation as Vascular Protective Agents
Current Vascular Pharmacology Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI
Current Pharmaceutical Design Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Detection of Biothiols Using Some Novel Chemosensors: An Overview
Mini-Reviews in Organic Chemistry The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry Dietary Regulation of Glucose Metabolism in Metabolic Syndrome
Current Vascular Pharmacology Obesity and Cardioprotection
Current Medicinal Chemistry Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders
Current Drug Metabolism Acute Coronary Syndromes as Auto-Inflammatory Disorders
Current Pharmaceutical Design